drugset / Trial / NCT02975700
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma.
Timeline
- Start
- 2017-01-31
- Primary completion
- 2018-08-31
- Completion
- 2024-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pexidartinib | Small molecule | 1000 mg | Oral |